Photocure starts up commercial operations in Spain
Photocure announces the start of its Hexvix® sales, marketing and direct distribution operations in Spain. In October 2020, Photocure had announced building its own commercial organization in the European markets formerly operated by business partners. The successful transition and successive launch of European Hexvix operations in the past years creates a robust platform for accelerated growth and expansion for Photocure.
Spain has a big market potential with over 58 000 TURBTs* performed per year. It has a high incidence of bladder cancer and one of the highest rates compared to its European neighbors, with 11 500 new cases diagnosed per year. Hexvix is reimbursed in Spain and has the support of local bladder cancer experts in key centers.
“This strategic step reinforces our commitment to improving bladder cancer detection and care globally. As we continue to expand our footprint in Europe, we are excited to collaborate with healthcare professionals in Spain to further our mission,” says Jane Healy, Photocure’s Vice President and General Manager, EMEA. “We have high expectations. The strength of the European guidelines recommending blue light cystoscopy with Hexvix, the evident support of local experts and data, and the positive reimbursement situation make us look very optimistically on this business opportunity.”
*TURBT: trans-urethral resection of bladder tumors